RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
16 November 2023 - 2:35PM
Business Wire
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a
clinical-stage biopharmaceutical company developing targeted
combination therapies, today announced the appointment of Michel
Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board
(SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology
Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy,
Professor of Oncology at Paris-Saclay University in France, and
Vice-Chair of ESMO GI.
Dr. Ducreux was trained in medicine, gastroenterology, and
gastrointestinal tract oncology at the University of Paris Sud. Dr.
Ducreux earned his master’s degree in biological sciences and PhD
in health sciences. He has held previous positions as assistant
physician and professor of oncology at the Gastrointestinal
Oncology Unit of Gustave Roussy and Paul Brousse Hospital in
Villejuif, France. He was a Medical Affairs Director at Gustave
Roussy from January 2011 to December 2019. He is the former Chair
of the European Organisation for Research and Treatment of Cancer
(EORTC) Gastrointestinal Tract Cancer Group and the former Chair of
the Gastrointestinal Group of the French Federation of Anticancer
Centers (FNCLCC). He is a co-editor for gastrointestinal oncology
of the European Journal of Cancer.
“I am excited to be working with my distinguished colleagues on
RenovoRx’s Scientific Advisory Board,” stated Dr. Ducreux. “I look
forward to contributing to the advancement of the Company’s novel
clinical programs that have the potential to revolutionize the
treatment of challenging cancers.”
Dr. Ducreux added, “Having previously worked on intra-arterial
and intra-tumoral delivery, what excites me most about RenovoRx’s
published data is its platform delivery mechanism. The
trans-arterial micro-perfusion platform appears to unlock
best-in-class improvements to increase local therapeutic tissue
concentration with deep tissue penetration to overcome dense tumor
microenvironments while avoiding dose-limiting systemic toxicities
beyond conventional intra-tumoral and traditional intra-arterial
delivery. This platform has the potential to extend across a
variety of high unmet needs beyond targeted delivery of gemcitabine
and pancreatic tumors.”
Professor Ducreux has published more than 500 scientific
articles, with papers for which he was the lead author, focusing on
the management of metastatic colorectal cancer, locally advanced
and metastatic pancreatic carcinoma, biliary tract carcinoma,
hepatocellular carcinoma, and treatment of neuroendocrine tumors.
He has been a speaker at over 200 invited lectures in various
national and international congresses.
“Dr. Ducreux is an internationally recognized clinical expert
and researcher who has made pioneering contributions to the field
of gastrointestinal cancers,” said Shaun Bagai, CEO of RenovoRx.
“We are honored to welcome Dr. Ducreux to our SAB. His extensive
knowledge on pancreatic and other gastrointestinal cancers and the
development of novel therapeutic approaches will be invaluable to
our R&D initiative. This appointment enhances the already deep
expertise resident in our growing SAB. We look forward to Dr.
Ducreux’s guidance as we advance our therapy platform,
TAMP™, for targeted treatment of difficult-to-access
tumors, like locally advanced pancreatic cancer (LAPC), and expand
to other clinical indications in our pipeline.”
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company
developing proprietary targeted combination therapies for high
unmet medical need with a goal to improve therapeutic outcomes for
cancer patients undergoing treatment. The Company’s proprietary
Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is
designed to ensure precise therapeutic delivery to directly target
the tumor while potentially minimizing a therapy’s toxicities
versus systemic (intravenous (IV) therapy). RenovoRx’s unique
approach to targeted treatment offers the potential for increased
safety, tolerance, and improved efficacy. Our Phase III lead
product candidate, RenovoGemTM, a novel oncology drug-device
combination product, is being investigated under a US IND that is
regulated by FDA 21 CFR 312 pathway. RenovoGem is currently being
evaluated for the treatment of locally advanced pancreatic cancer
(LAPC) by the Center for Drug Evaluation and Research (the drug
division of FDA.) RenovoRx is committed to transforming the lives
of patients by delivering innovative solutions to change the
current paradigm of cancer care. RenovoGem is currently under
investigation for TAMP therapeutic delivery of gemcitabine and has
not been approved for commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on
Facebook, LinkedIn, and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934, including but
not limited to statements regarding our clinical trials and
studies, including anticipated timing, statements regarding the
potential of RenovoCath®, RenovoGemTM or TAMPTM or regarding our
ongoing TIGeR-PaC Phase III clinical trial study in LAPC,
statements regarding the potential for our product candidates to
treat or provide clinically meaningful outcomes for certain medical
conditions or diseases, and our preliminary financial results, cash
position and related ability to continue as a going concern.
Statements that are not purely historical are forward-looking
statements. The forward-looking statements contained herein are
based upon our current expectations and beliefs regarding future
events, many of which, by their nature, are inherently uncertain,
outside of our control and involve assumptions that may never
materialize or may prove to be incorrect. These may include
estimates, projections and statements relating to our research and
development plans, clinical trials, therapy platform, business
plans, objectives and expected operating results, which are based
on current expectations and assumptions that are subject to known
and unknown risks and uncertainties that may cause actual results
to differ materially from those expressed or implied by these
forward-looking statements. These statements may be identified
using words such as “may,” “expects,” “plans,” “aims,”
“anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and
“potential,” or the negative of these terms or other comparable
terminology regarding RenovoRx’s expectations strategy, plans or
intentions, although not all forward-looking statements contain
these words. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, that could cause
actual events to differ materially from those projected or
indicated by such statements, including, among other things: the
timing of the initiation, progress and potential results of our
preclinical studies, clinical trials and our research programs; the
possibility that interim results may not be predictive of the
outcome of our clinical trial, which may not demonstrate sufficient
safety and efficacy to support regulatory approval of our product
candidate, or the regulatory authority may disagree with our
interpretation of the data; research and clinical development plans
and timelines, and the regulatory process for our product
candidates; future potential regulatory milestones for our product
candidates, including those related to current and planned clinical
studies; our ability to use and expand our therapy platform to
build a pipeline of product candidates; our ability to advance
product candidates into, and successfully complete, clinical
trials; the timing or likelihood of regulatory filings and
approvals; our estimates of the number of patients who suffer from
the diseases we are targeting and the number of patients that may
enroll in our clinical trials; the commercialization potential of
our product candidates, if approved; our ability and the potential
to successfully manufacture and supply our product candidates for
clinical trials and for commercial use, if approved; future
strategic arrangements and/or collaborations and the potential
benefits of such arrangements; our estimates regarding expenses,
future revenue, capital requirements and needs for additional
financing and our ability to obtain additional capital; the
sufficiency of our existing cash and cash equivalents to fund our
future operating expenses and capital expenditure requirements; our
ability to retain the continued service of our key personnel and to
identify, hire and retain additional qualified personnel; the
implementation of our strategic plans for our business and product
candidates; the scope of protection we are able to establish and
maintain for intellectual property rights, including our therapy
platform, product candidates and research programs; our ability to
contract with third-party suppliers and manufacturers and their
ability to perform adequately; the pricing, coverage and
reimbursement of our product candidates, if approved; developments
relating to our competitors and our industry, including competing
product candidates and therapies; negative impacts of the ongoing
COVID-19 pandemic on our operations; and other risks. Information
regarding the foregoing and additional risks may be found in the
section entitled “Risk Factors” in documents that we file from time
to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the
date hereof, and RenovoRx does not undertake any obligation to
update publicly such forward-looking statements to reflect
subsequent events or circumstances, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231116495144/en/
Investor Contact: KCSA Strategic Communications Valter
Pinto or Jack Perkins T:212-896-1254 renovorx@kcsa.com
Media Contact: Kimberly Ha KKH Advisors 917-291-5744
kimberly.ha@kkhadvisors.com
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024